Bristol-Myers Squibb Co news

   Watch this stock
Showing stories 1 - 10 of about 165   

Articles published

BMY 73.25 +0.29 (0.40%)
price chart
Bristol-Myers Squibb Co (NYSE:BMY)Analyst Research Summary:
Bristol-Myers Squibb Co (NYSE:BMY)stock is currently trading at about $70.32 and lots of rating firms seem to have a target price set on the stock.
Bristol-Myers Squibb Co (BMY) Bucks Market Sell-Off on Upbeat Drug News  Schaeffers Research (blog)
Bristol-Myers Squibb Co Wins a Sixth Breakthrough Tag for Opdivo  Bidness ETC
PsiOxus, Bristol-Myers Squibb To Evaluate Combination Of Opdivo, Enadenotucirev
(RTTNews.com) - PsiOxus Therapeutics, Ltd. announced Thursday an exclusive immuno-oncology clinical collaboration agreement with Bristol-Myers Squibb Co. ( BMY ) to evaluate the combination of Opdivo and Enadenotucirev to treat a range of tumor ...
Bristol-Myers Squibb Company Upside Stock Momentum at Extreme Strength
This is a momentum stock rating analysis for Bristol-Myers Squibb Company (NYSE:BMY) . The company has a five bull momentum rating which indicates extreme strength.
Bristol-Myers Squibb's bladder cancer treatment granted breakthrough therapy ...
Bristol-Myers Squibb Co. BMY, -0.41% said Monday that its bladder cancer treatment, Opdivo, was granted breakthrough therapy designation by the Food and Drug Administration.
What Analyst Advised about Stocks? Bristol-Myers Squibb Company (NYSE:BMY ...
Bristol-Myers Squibb Company (NYSE:BMY) surged +1.91% and ended at $73.00. The stock's market capitalization arrived at $121.86B and total traded volume was 6.54 million shares.
Bristol-Myers Squibb (NYSE:BMY) Analyst Estimates And Rating  Zergwatch
HC Stocks to Path: Johnson & Johnson (NYSE:JNJ), Bristol-Myers Squibb Co ...  share market updates (press release)
Is Bristol-Myers Squibb Co (NYSE:BMY) an Incredibly Valuable Stock?
[Capital Cube] Bristol-Myers Squibb Co (NYSE:BMY)(TREND ANALYSIS) has a fundamental score of 59 and has a relative valuation of OVERVALUED.
Analysts Advise About Bristol-Myers Squibb Co (NYSE:BMY)  Zergwatch
Two Movers inside Analysts Radar: Bristol-Myers Squibb Company (NYSE:BMY ...  Street Updates
Analyst Rating Update on Bristol-Myers Squibb Company (BMY)
Bristol-Myers Squibb Company (NYSE:BMY) has an average broker rating of 2.32, which is interpreted as a Buy, as rated by 17 equity analysts.
Highlights of Analyst's Revenue Viewpoints: Bristol-Myers Squibb Company ...  Is stories
Stock under consideration: Bristol-Myers Squibb Company (NYSE:BMY)  News Oracle
News Sentiment For Bristol-Myers Squibb Company (NYSE:BMY)
Bristol-Myers Squibb Company (NYSE:BMY) has been given a sentiment score of 0.28 by research firm. Coming to the sentiment scale, the impact score measured on daily basis stands on a 1-100 scale.
Analysts watching two Stocks: Bristol-Myers Squibb Company (NYSE:BMY) , Sanofi ...
On 6/29/2016, Bristol-Myers Squibb Company (NYSE:BMY) ended trading session higher at $73.00 with +1.91%. The company traded a volume of 6.54 million shares as comparison to average volume of 5.92 million shares.
Here's Why Leerink Partners Is More Positive On Bristol-Myers Squibb Co (BMY ...
Leerink Partners LLC analyst, Seamus Fernandez sharpened his pencils on Keytruda after Merck & Co., Inc. (NYSE:MRK) announced that patients who received Keytruda fared better compared to those who received chemotherapy.
Could Merck Beat Bristol-Myers To Market?  Seeking Alpha